NCT05775042View on ClinicalTrials.gov

Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 8, 2023

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
IgA Nephropathy
Interventions
BIOLOGICAL

CM338

CM338 injection

Trial Locations (1)

Unknown

RECRUITING

Peking University First Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY

NCT05775042 - Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy | Biotech Hunter | Biotech Hunter